

# TRIOCHEM PRODUCTS LIMITED

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road,  
Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 31580  
Fax: 00 91 (22) 2202 4657 E-mail: [info@amphray.com](mailto:info@amphray.com)

Website: [www.triochemproducts.com](http://www.triochemproducts.com) Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 201229 2020; 12<sup>th</sup> February 2021

To  
BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai: 400 001.  
Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015


Pursuant to Notice of Board meeting dated 2<sup>nd</sup> February 2021 the Board meeting was held on today Friday, 12<sup>th</sup> February, 2020 at 2.00 p.m. at 4<sup>th</sup> Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

1. The Board approved the Unaudited Financial Results for the quarter and nine months ended on 31<sup>st</sup> December 2020, as reviewed by the Audit Committee, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
2. The Board noted and took on records the Limited Review Report for the quarter and nine months ended on 31<sup>st</sup> December 2020 as placed before the Board.
3. Take notes on the compliance for the quarter and nine months ended 31<sup>st</sup> December 2020
4. Board Meeting commenced at 2.00 p.m. and concluded at 3.10 p.m.

You are requested to take note of the same.

Thanking you,  
Yours faithfully,

For **TRIOCHEM PRODUCTS LIMITED**

  
**RAMU S. DEORA**  
**DIRECTOR**  
**DIN: 00312369**  
**Place: Mumbai**



**Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")**

1. We have reviewed the accompanying statement of unaudited financial results of **TRIOCHEM PRODUCTS LIMITED ("Company")** for the quarter and nine months ended December 31, 2020 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
2. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP  
Chartered Accountants  
Firm Registration No: 104746W/W100096

KUNAL SUMANT  
VAKHARIA

Digitally signed by KUNAL SUMANT VAKHARIA  
DN: cn=KUNAL SUMANT VAKHARIA, o=KUNAL SUMANT VAKHARIA,  
sn=KUNAL SUMANT VAKHARIA, email=KUNALSUMANTVAKHARIA@KUNALSUMANTVAKHARIA.COM,  
c=IN, ou=KUNAL SUMANT VAKHARIA, postalCode=400007,  
serialNumber=1, cn=KUNAL SUMANT VAKHARIA  
Date: 2021.02.12 14:43:43 +05'30'

Kunal Vakharia  
Partner  
Membership No.: 148916  
UDIN: 21148916AAAABR3677

Place: Mumbai  
Date: 12<sup>th</sup> February 2021



**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

 Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,


PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

 E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001. Website: <a href="http://www.triochemproducts.com">www.triochemproducts.com</a> CIN : L24249MH1972PLC015544							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020							
(Rs in Lakh) Except EPS							
Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-20 (Unaudited)	30-Sep-20 (Unaudited)	31-Dec-19 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-19 (Unaudited)	31-Mar-20 (Audited)
1	<b>Income</b>						
	(a) Revenue from Operations	394.50	225.86	541.16	620.36	855.52	2,003.18
	(b) Other Income	0.16	4.38	12.93	5.84	13.25	46.63
	<b>Total Income From Operations</b>	<b>394.66</b>	<b>230.24</b>	<b>554.09</b>	<b>626.20</b>	<b>868.77</b>	<b>2,049.81</b>
	<b>Expenses</b>						
	(a) Cost of Materials Consumed	(0.00)	226.06	424.70	644.54	424.70	968.86
	(b) Purchase of stock in trade	-	-	4.78	-	4.78	37.55
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	360.19	(47.76)	(99.57)	(111.88)	102.98	354.67
	(d) Employees Benefit Expenses	16.74	16.89	17.04	50.52	51.92	82.33
	(e) Finance Costs	2.47	4.97	9.36	9.53	17.19	22.97
	(f) Depreciation and Amortisation Expenses	3.46	3.46	4.21	10.34	12.57	16.68
	(g) Other Expenditure	21.40	33.79	27.33	75.23	84.93	111.57
	<b>Total expenses</b>	<b>404.26</b>	<b>237.41</b>	<b>387.85</b>	<b>678.28</b>	<b>699.08</b>	<b>1,594.63</b>
3	<b>Profit before exceptional items and tax</b>	<b>(9.60)</b>	<b>(7.17)</b>	<b>166.24</b>	<b>(52.08)</b>	<b>169.69</b>	<b>455.18</b>
4	Exceptional items	-	-	-	-	-	-
5	<b>Profit/ (Loss) before tax</b>	<b>(9.60)</b>	<b>(7.17)</b>	<b>166.24</b>	<b>(52.08)</b>	<b>169.69</b>	<b>455.18</b>
6	Tax Expense						
	(a) Current tax	(0.00)	-	41.73	0.02	44.02	117.33
	(b) Deferred tax	(2.42)	(1.73)	1.71	(12.98)	(1.80)	(2.43)
	<b>Total tax expenses</b>	<b>(2.43)</b>	<b>(1.73)</b>	<b>43.44</b>	<b>(12.97)</b>	<b>42.22</b>	<b>114.90</b>
7	<b>Net Profit/ (Loss) for the period</b>	<b>(7.18)</b>	<b>(5.43)</b>	<b>122.80</b>	<b>(39.12)</b>	<b>127.47</b>	<b>340.28</b>
	<b>Other Comprehensive Income (Net of Taxes)</b>						
	(A)(i). Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	(B)(i). Item that will not be reclassified to profit or loss	0.43	(1.06)	(0.03)	(0.52)	(0.32)	(0.30)
	(ii). Income tax relating to items that will not be reclassified to profit or loss	(0.11)	0.27	-	0.13	0.08	0.08
	<b>Total other Comprehensive Income (net of taxes)</b>	<b>0.32</b>	<b>(0.79)</b>	<b>(0.03)</b>	<b>(0.39)</b>	<b>(0.24)</b>	<b>(0.22)</b>
9	<b>Total Comprehensive Income for the period</b>	<b>(6.85)</b>	<b>(6.22)</b>	<b>122.77</b>	<b>(39.50)</b>	<b>127.23</b>	<b>340.06</b>
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year						1,193.14
12	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualised)						
	Basic / Diluted EPS (in Rs.)	(2.93)	(2.22)	50.12	(15.97)	52.03	138.89



**TRIOCHEM PRODUCTS LIMITED**

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4<sup>th</sup> Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mail: [info@amphray.com](mailto:info@amphray.com) Website: [www.triochemproducts.com](http://www.triochemproducts.com)

Corporate Identity Number: L24249MH1972PLC015544



Notes:	
1)	The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12th February, 2021. The Statutory auditors of the company has carried out a limited review of aforesaid results.
2)	The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
3)	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
4)	Operations during the quarter continued to be impacted by measures to contain covid-19 pandemic. The business gathered momentum, though recovery has been gradual and partial. Accordingly, the results for the quarter are not comparable with those for the previous quarter and corresponding quarter of previous year. Based on the information available upto date, the Group expects to recover the carrying value of its assets.
5)	The date of implementation of the Code on Wages, 2019 and the Code on Social Security 2020 is yet to be notified by the Government. The Ministry of Labour and Employment has released draft rules for the Code on Social Security 2020 on November 13, 2020, and has invited suggestions from Stakeholders which are under active consideration by the Ministry. The Company will assess the impact of these codes and give effect in the financial result when the Rules/Schemes thereunder are notified.
6)	The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR &amp; CEO

DIN : 00312369

Place: Mumbai

Dated: 12th February, 2021



**TRIOCHEM PRODUCTS LIMITED**

Registered Office : Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: [www.triochemproducts.com](http://www.triochemproducts.com)

CIN : L24249MH1972PLC015544

**EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020**

(Rs in Lakh) Except EPS

Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-20 (Unaudited)	30-Sep-20 (Unaudited)	31-Dec-19 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-19 (Unaudited)	31-Mar-20 (Audited)
1	Net Operating Income	394.66	230.24	554.09	626.20	868.77	2,049.81
2	Profit / (Loss) for the period (before Interest, Depreciation, Taxes, Exceptional and / or Extraordinary items)	(3.68)	1.26	179.81	(32.22)	199.45	494.83
3	Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(9.60)	(7.17)	166.24	(52.08)	169.69	455.18
4	Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(7.18)	(5.43)	122.80	(39.12)	127.47	340.28
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income	0.32	(0.79)	(0.03)	(0.39)	(0.24)	(0.22)
6	Equity share capital (Face value of Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
7	Reserve (excluding Revaluation Reserves as shown in the Balance Sheet of previous year)						1,193.14
3	Earnings per equity share (EPS) (of Rs. 10/- each) (for continuing and discontinued operations)						
	a) Basic (not annualized)	(2.93)	(2.22)	50.12	(15.97)	52.03	138.89
	b) Diluted (not annualized)	(2.93)	(2.22)	50.12	(15.97)	52.03	138.89


**Notes:**

- The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12th February, 2021. The Statutory auditors of the company has carried out a limited review of aforesaid results.
- The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- Operations during the quarter continued to be impacted by measures to contain covid-19 pandemic. The business gathered momentum, though recovery has been gradual and partial. Accordingly, the results for the quarter are not comparable with those for the previous quarter and corresponding quarter of previous year. Based on the information available upto date, the Group expects to recover the carrying value of its assets.
- The date of implementation of the Code on Wages, 2019 and the Code on Social Security 2020 is yet to be notified by the Government. The Ministry of Labour and Employment has released draft rules for the Code on Social Security 2020 on November 13, 2020, and has invited suggestions from Stakeholders which are under active consideration by the Ministry. The Company will assess the impact of these codes and give effect in the financial result when the Rules/Schemes thereunder are notified.
- The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai

Dated: 12th February, 2021

  
**RAMU S. DEORA**  
 DIRECTOR & CEO  
 DIN: 00312369

